{"id":941040,"date":"2026-03-02T10:49:58","date_gmt":"2026-03-02T15:49:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/"},"modified":"2026-03-02T10:49:58","modified_gmt":"2026-03-02T15:49:58","slug":"hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/","title":{"rendered":"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MIRAMAR, Fla., March  02, 2026  (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and disease, today reported that, on February 26, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with all continued listing rules of The Nasdaq Capital Market.\u00a0<\/p>\n<p align=\"justify\">Dr. Hing C. Wong, the Company\u2019s Founder and CEO, stated \u201cWe appreciate the discretion of the Nasdaq Panel to provide us with the time we needed to regain compliance with the Equity Rule. Regaining compliance allows us to continue to access the public markets for capital we need to advance our first-in-class immunotherapeutic drugs that we believe will transform the way we treat autoimmune diseases, cancer and other senescence-associated diseases.\u201d<\/p>\n<p>\n        <strong>About HCW Biologics:<\/strong>\n      <\/p>\n<p align=\"justify\">HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company\u2019s immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation \u2014 and in doing so, improve patients\u2019 quality of life and possibly extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to the cause for senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening. The Company lead product candidate for its autoimmune program is HCW9302, subcutaneously injectable, first-in-kind interleukin-2 (\u201cIL-2\u201d) fusion molecule with a tissue-factor scaffold that was constructed using the Company\u2019s TOBI\u2122 platform technology. HCW9302 is currently being evaluated in a Phase 1 clinical study in patients with alopecia areata, which initiated in November 2025 (NCT07049328). The Company has identified two preclinical lead product candidates for internal development constructed with its proprietary TRBC drug discovery and development platform, constructed with a protein-based scaffold. HCW11-018b (\u201cBig BiTE\u201d) is a tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors. HCW11-040 is a pembrolizumab-based, tetra-valent immune checkpoint inhibitor. To improve efficacy, HCW11-040 is equipped with other moieties in addition to pembrolizumab which neutralizes the immunosuppressive cytokine, TGF-\u03b2, and activates effector immune cell responses. A key aspect of the Company\u2019s clinical development and financing strategy is to focus on its business development programs. To date, the Company has entered two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at\u00a0<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oIsJ0DlVZI3EvWXQEPVkPngqhKfgbF9xvssVPhZhQhSNShYDxGvlORCtrQ3xFblba96tF3ISX_WKIrzB0JL6Bs9NORcWCEnapwFx55r68URRU7K04zgWxZRdssp40dRa\" rel=\"nofollow\" target=\"_blank\">https:\/\/hcwbiologics.com\/pipeline\/<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements:<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast\u201d or other similar words and include, the Company\u2019s ability to improve or extend healthspan; to extend longevity; to develop new immunotherapeutic treatments for chronic inflammation and age-related diseases; to develop treatments with its drug discovery platforms; the Company\u2019s ability to execute its compliance plan and regain compliance with Nasdaq continued listing requirements; and the Company\u2019s ability to raise additional funds.\u00a0 Similarly, statements that describe the Company\u2019s objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company\u2019s current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company\u2019s control. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The Company\u2019s actual results may differ materially from those indicated in the forward-looking statements.\u00a0 Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled \u201cRisk Factors\u201d in the Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the \u201cSEC\u201d) on March 28, 2025, the latest Quarterly Report on Form 10-Q filed with the SEC on November 14, 2025, and in other filings filed from time to time with the SEC.<\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Rebecca Byam <br \/>Chief Financial Officer <br \/>HCW Biologics Inc. <br \/>RebeccaByam@hcwbiologics.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTFmMWQwN2UtYWZmZi00Yjc5LWIyZTktN2NmNmIwZmZlYmMwLTEyMjE3NTEtMjAyNi0wMy0wMi1lbg==\/tiny\/HCW-Biologics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and disease, today reported that, on February 26, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with all continued listing rules of The Nasdaq Capital Market.\u00a0 Dr. Hing C. Wong, the Company\u2019s Founder and CEO, stated \u201cWe appreciate the discretion of the Nasdaq Panel to provide us with the time we needed to regain compliance with the Equity Rule. Regaining compliance allows us to continue to access &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941040","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and disease, today reported that, on February 26, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with all continued listing rules of The Nasdaq Capital Market.\u00a0 Dr. Hing C. Wong, the Company\u2019s Founder and CEO, stated \u201cWe appreciate the discretion of the Nasdaq Panel to provide us with the time we needed to regain compliance with the Equity Rule. Regaining compliance allows us to continue to access &hellip; Continue reading &quot;HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T15:49:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter\",\"datePublished\":\"2026-03-02T15:49:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/\"},\"wordCount\":786,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/\",\"name\":\"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=\",\"datePublished\":\"2026-03-02T15:49:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/","og_locale":"en_US","og_type":"article","og_title":"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - Market Newsdesk","og_description":"MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) &#8212; HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and disease, today reported that, on February 26, 2026, the Nasdaq Hearings Panel (the \u201cPanel\u201d) of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d or the \u201cExchange\u201d) found that the Company regained compliance with all continued listing rules of The Nasdaq Capital Market.\u00a0 Dr. Hing C. Wong, the Company\u2019s Founder and CEO, stated \u201cWe appreciate the discretion of the Nasdaq Panel to provide us with the time we needed to regain compliance with the Equity Rule. Regaining compliance allows us to continue to access &hellip; Continue reading \"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-02T15:49:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter","datePublished":"2026-03-02T15:49:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/"},"wordCount":786,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/","name":"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=","datePublished":"2026-03-02T15:49:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzY1MCM3NDYxMjI4IzIyMTAxOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941040"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941040\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}